Posted inBiotechnology
Sling’s oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3
Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) trial,…




